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Abstract
Background: Neonatal diarrhea remains one of the main causes of morbi-mortality in dairy calves under artificial
rearing. It is often caused by infectious agents of viral, bacterial, or parasitic origin. Cows vaccination and colostrum
intake by calves during the first 6 h of life are critical strategies to prevent severe diarrhea but these are still
insufficient. Here we report the field evaluation of a product based on IgY antibodies against group A rotavirus
(RVA), coronavirus (CoV), enterotoxigenic Escherichia coli, and Salmonella sp. This product, named IgY DNT, has been
designed as a complementary passive immunization strategy to prevent neonatal calf diarrhea. The quality of the
product depends on the titers of specific IgY antibodies to each antigen evaluated by ELISA. In the case of the viral
antigens, ELISA antibody (Ab) titers are correlated with protection against infection in calves experimentally
challenged with RVA and CoV (Bok M, et al., Passive immunity to control bovine coronavirus diarrhea in a dairy herd
in Argentina, 2017), (Vega C, et al., Vet Immunol Immunopathol, 142:156–69, 2011), (Vega C, et al., Res Vet Sci, 103:
1–10, 2015). To evaluate the efficiency in dairy farms, thirty newborn Holstein calves were randomly assigned to IgY
DNT or control groups and treatment initiated after colostrum intake and gut closure. Calves in the IgY DNT group
received 20 g of the oral passive treatment in 2 L of milk twice a day during the first 2 weeks of life. Animals were
followed until 3 weeks of age and diarrhea due to natural exposure to infectious agents was recorded during all
the experimental time.
Results: Results demonstrate that the oral administration of IgY DNT during the first 2 weeks of life to newborn
calves caused a delay in diarrhea onset and significantly reduced its severity and duration compared with untreated
calves. Animals treated with IgY DNT showed a trend towards a delay in RVA infection with significantly shorter
duration and virus shedding compared to control calves.
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Conclusions: This indicates that IgY DNT is an effective product to complement current preventive strategies
against neonatal calf diarrhea in dairy farms. Furthermore, to our knowledge, this is the only biological product
available for the prevention of virus-associated neonatal calf diarrhea.
Keywords: Infectious neonatal calf diarrhea, IgY antibody, Rotavirus, Passive treatment
Background
Neonatal calf mortality rates are still unacceptably high
on dairy farms, despite all the advances in dairy herd
health and productivity [11, 25, 37]. Diarrhea is the lead-
ing cause of calf mortality [34]. Neonatal calf diarrhea is
generally caused by infectious agents and is a very com-
mon disease in bovine production, leading to substantial
economic losses. The most common pathogens involved
are bovine group A rotavirus (RVA), bovine coronavirus
(CoV), Cryptosporidium parvum, Salmonella spp. and
pathogenic Escherichia coli, especially in animals youn-
ger than one-month-old [3, 6, 11, 17]. Antimicrobials
are often systematically used to prevent and treat neo-
natal calf diarrhea, even though a proper etiological
diagnosis is rarely carried out. This leads to the unneces-
sary and excessive use of antibiotics in food animal spe-
cies and the potential development of resistant bacteria
and severe dysbiosis, the impairment of gut microbiome.
The loss of beneficial bacteria with an overgrowth of
harmful organisms will increase the risk of diseases [9].
This has prompted the ban on sub-therapeutic usage of
antibiotics in many countries [14, 34]. On the other
hand, diagnostic testing for the most common infectious
agents associated with neonatal calf diarrhea is not
always available and/or can not be performed on time.
This situation highlights the need for alternative solu-
tions to antibiotics that could also be a viable alternative
strategy to control virus- and parasite-associated
diarrhea, which are not sensitive to antibiotics. Several
passive immune therapies based on antibodies from
different sources have been proposed and tested as treat-
ments for infectious neonatal calf diarrhea [20, 21, 23,
24, 27, 28, 41, 42]. However, there are no commercially
available biological products based on passive immunity
for neonatal diarrhea. IgY antibodies (Abs) are recog-
nized as an attractive approach as they are safe, easy-to-
produce, and effective for the prevention and treatment
of infectious neonatal calf diarrhea. Furthermore, IgY
Abs can be produced in cost-effective production sys-
tems under controlled conditions [13, 14, 36, 41, 42].
We have previously determined the IgY Ab titers to bo-
vine RVA and CoV needed to prevent virus-associated
diarrhea in newborn calves under controlled conditions
resembling artificial rearing [7, 41, 42]. Based on these
previous findings, we decided to develop a standardized
biological product (named IgY DNT) that can be mas-
sively used in dairy farms for the prevention and treat-
ment of infectious neonatal calf diarrhea. Several
experimental field trials were performed in Argentina at
dairy farms suffering a high incidence of neonatal calf
diarrhea with promising results [43]. However, a
controlled and daily monitored field trial to estimate the
efficacy of this product was still missing.
This study aimed to determine the efficacy of IgY
DNT on neonatal calf diarrhea incidence, onset, dur-
ation and etiology in dairy calves raised under regular
artificial conditions during the first 3 weeks of life in a
dairy herd in Argentina.
Results
In this study, 30 newborn calves were randomly assigned
to an experimental group treated with 2 L of fresh milk
supplemented with 20 g of IgY DNT (10mg/mL, n = 15
calves) or to a group fed only with 2 L of fresh milk dur-
ing the first 2 weeks of life (n = 15 calves). All animals
were raised following the same management protocol
and care attention was provided by veterinarians and/or
qualified technicians at least twice a day. The dairy farm
“El Mangrullo” was selected because it showed a history
of infectious neonatal diarrhea in the past years. During
the experimental time (from birth and until the third
week of life), no adverse reactions associated with the
treatment were observed in any calf from IgY DNT
treatment group (G1). One animal in the control group
(G2) died at 10 days-of-life due to ulcerative colitis of
unknown reasons. All calves remained at the dairy farm
after the end of the experiment, under regular manage-
ment conditions.
The occurrence of neonatal diarrhea as a result of nat-
ural infection was registered daily for each calf until the
third week of life (22 days). As expected, diarrhea was
present in both groups of calves. However, in IgY DNT
group two of the animals (2/15, 13%) did not develop
diarrhea along the experimental time, while 100% (15/
15) of the untreated animals showed at least one diar-
rhea episode (fecal score ≥ 2; Table 1), despite no signifi-
cant differences were observed in the diarrhea survival
curves and the mean days to diarrhea onset among
groups (Fig. 1). Diarrhea severity was determined as the
average of the AUC of the daily fecal score for each
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group of calves (Fig. 1). Animals in IgY DNT group
showed significantly lower diarrhea severity (Mann
Whitney test; p = 0.0035). This was associated with a sig-
nificantly shorter duration of diarrhea, as calves in IgY
DNT group presented this condition for less than 2 days
in average (1.53 days, Mann Whitney test; p = 0.0035,
Table 1), compared with control calves that presented
almost three times longer diarrhea duration (4.64 days in
average, Table 1). Furthermore, in IgY DNT group only
one calf developed diarrhea for four consecutive days,
while 38.5% (5/13) of diarrhea-affected calves showed
this condition for only 1 day.
The presence of neonatal calf diarrhea-associated
pathogens was further investigated in all fecal samples
Table 1 Diarrhea and group A bovine rotavirus infection onset and duration
Treatment Group % diarrhea
affected calves
Diarrhea onset
(days of life)
Diarrhea
duration (days)
% RVA
affected calves
RVA shedding
onset
(days of life)
RVA shedding
duration (days)
G1= IgY DNT 86% (13/15) 9.26 1.53 a 47% (7/15) 11.71c 1.00 e
G2 = no Ab treatment 100% (15/15) 8.29 4.64 b 47% (7/15) 7.43 d 5.86 f
Diarrhea was assessed daily in all calves (fecal score ≥ 2). A calf showing at least one episode of fecal score ≥ 2 was defined as diarrhea positive. Diarrhea onset
and duration were computed as an average from the animals presenting this clinical condition on each experimental group. RVA was determined in all fecal
samples from diarrhea-affected calves by ELISA and viral shedding onset and duration were computed as average from animals on each experimental group.
Means in the same column with different superscript upper case letters differ significantly by Mann Whitney test: a-b p-value = 0.0035; c-d p-value = 0.0320;
e-f p-value = 0.0020
Fig. 1 Diarrhea analysis in IgY DNT and non-treated calves. a- Kaplan-Meier survival curve of diarrhea for both animal groups. b- Diarrhea onset
was considered as the first days with a fecal score equal to or higher than 2. It was recorded for each calf and the average for each experimental
group was then calculated. c- Diarrhea duration was recorded for each calf as the number of consecutive days with a fecal score > 2. The average
for each group was calculated. d- Diarrhea severity was estimated as the area under the fecal scores curve (AUC) for each calf was determined
and then the average AUC for diarrhea was calculated for each group. The “*” indicates significant differences among the experimental groups of
calves by Mann Whitney Test, with corresponding p-values expressed on each panel
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collected. No ETEC or Salmonella spp. were detected in
any of the samples, while one calf from the control
group (G2) shed CoV in feces at 24 h of life but did not
develop diarrhea, so it was no further examined. Group
A Rotavirus was shed by 47% (7/15) of the animals from
each experimental group (Table 1). However, only 28%
(2/7) of the animals in IgY group (G1) present RVA-
associated diarrhea while all (100%, 7/7) calves in G2
showed this clinical condition in association with RVA
detection in feces. Calves in IgY DNT group (G1)
showed a trend towards a delay in the onset of RVA
shedding (11.71 days) compared with animals in the con-
trol group (G2; 7.43 days). Furthermore, RVA infection
survival curves did not differ significantly among groups
(Fig. 2). Another important difference observed was a
significantly lower viral shedding (AUC) in calves in IgY
DNT treated group than in control group animals
(Mann Whitney test; p = 0.002; Fig. 2).
A premise of the experimental design was that all the
animals recruited for this study should present statisti-
cally similar Ab titers in serum to bovine RVA and CoV
after colostrum intake. The geometric mean IgG1 Ab ti-
ters to RVA and CoV in calves’ sera at 1, 8, 15 and 22
days of life were similar among calves in G1 and G2 (by
a mixed model for repeated measures, data not shown),
even when animals in the control group (G2) developed
RVA-associated diarrhea. The geometric mean IgG1 Ab
titers to RVA immediately after colostrum intake (day 1
of life) were 19,700 in G1 and 28,500 in G2, while ELISA
IgG1 titers to CoV were 12,400 in G1 and 13,600 in G2.
These values are consistent with the expected IgG1 Ab
titers in serum for calves receiving colostrum from vac-
cinated dams [7, 27]. As expected, ELISA IgG1 Ab titers
to RVA and CoV showed a trend towards lower titers
along the experimental time (22 days of life). By the end
of the experiment, ELISA IgG1 Ab titers to RVA were
7800 in G1 and 10,000 in G2, while for CoV were 3100
in G1 and 3400 in G2.
Discussion
Neonatal diarrhea is still an important concern in dairy
herds that is not completely prevented with good man-
agement and sanitary practices available, likely because
of the multi-factorial nature of the disease [11, 18]. In
the United States, diarrhea is the most common disease
condition in pre-weaned dairy calves, accounting for
56.4% of deaths [38]. There are no virus-specific therap-
ies available, while several bacteria strains are now
antibiotic-resistant due to the misuse of antibiotics in
veterinary medicine [18, 34]. More than 50% of all neo-
natal diarrhea appears during the first week, and only
15% occur after the second week of life [4, 5]. Interest-
ingly, half of the neonatal deaths are associated with
diarrhea, while respiratory diseases seem to represent
another 15% [1, 39].
Thirty newborn calves were recruited to evaluate the
IgY DNT performance for controlling neonatal calf diar-
rhea under natural challenge. All animals in the control
group (G2) developed diarrhea at least once during the
first 3 weeks of life. This result demonstrates that even
when high Ab titers in calves’ sera are assured, implying
optimal dams’ vaccination and a proper colostrum in-
take, the natural challenge with infectious agents associ-
ated with neonatal diarrhea overcomes the passive
immunity conferred by maternal Abs as well as the neo-
natal primary immune response. To our knowledge, this
is the first report of a commercially available biological
product based on IgY Abs to control bovine neonatal
diarrhea of infectious origin. A key feature in the devel-
opment of this product was the evaluation of the ELISA
IgY Ab titers needed against each infectious agent and
the optimization of a product containing not only these
IgY Ab titers but also meeting all the microbiological re-
quirements for oral administration to neonatal calves.
The biological product developed based on IgY Abs has
shown to be safe for calves while serving to reduce the
incidence and severity of infectious diarrhea. This pro-
tection has shown to be dependent on virus-specific IgY
Ab titers present in the product and the duration of the
treatment, as it is a passive immune strategy [41, 42].
The development of IgY DNT was done considering the
minimum amount of IgY Abs per dose needed to protect
calves at an acceptable price for milk producers (regard-
ing the costs of calf feeding, diarrhea treatment, calf
death, dam’s reposition, etc.). This study shows that
RVA-associated neonatal calf diarrhea in dairy calves
can be significantly reduced with the preventive adminis-
tration of a product based on virus-specific IgY Abs.
Calves treated presented a delay in RVA infection, six
times shorter duration of virus shedding, and seven
times lower titers of virus shedding compared with the
untreated control animals. This implies lower environ-
mental contamination, reducing the chances of the virus
spreading and consequent diarrhea outbreaks. Due to
the experimental design that implied only the environ-
mental challenge of animals, no conclusions can be
made regarding the role of IgY DNT treatment on other
infectious agents associated with neonatal calf diarrhea,
as only RVA was detected and CoV was only detected
once in an asymptomatic animal in this study. The
antigen-detection assays performed were the ones cur-
rently used by the Diagnosis Service Unit at INTA for
bacteria and viruses in diarrhea in calves. Other more
sensitive assays could have been performed to determine
the circulation of infectious agents in feces, like qPCR.
However, the presence of significantly low amounts of
viruses and/or bacteria, which are usually ubiquitous in
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the dairy environment, cannot be associated with diar-
rhea [3, 6, 8, 16–18]. Parasites were not evaluated in this
study as IgY DNT does not contain IgY Abs against
them. Particularly, Cryptosporidium parvum has been
systematically detected in the last years as an infectious
agent that could be associated with diarrhea in calves [4,
10, 17]. However, as it is now being systematically
detected in feces of symptomatic and asymptomatic
calves in Argentina [17], efforts are being made to
include at least C. parvum in IgY DNT production.
Several passive immune therapies based on antibodies
from different sources have been proposed and tested as
treatments for infectious neonatal calf diarrhea but, to
our knowledge, no other biological products are avail-
able in the market [19, 20, 24]. Regarding IgY Abs, there
are several reports of its efficacy for neonatal calf diar-
rhea prevention and treatment, where IgY Abs titer
shown to be critical [14]. There are some milk supple-
ments based on IgY Abs for calves but these do not have
controlled IgY Ab titers against diarrhea-associated
infectious agents. It has been shown that the supplemen-
tation of the milk diet with immune colostrum signifi-
cantly reduced diarrhea and delayed viral shedding onset
[22, 28]. However, the development of a product based
on colostrum for milk supplementation was not an
industrially scalable alternative.
Another relevant finding associated with this heterol-
ogous passive treatment based on IgY Abs is that it
modulates the mucosal immune response in the gut to-
wards higher numbers of Ab secreting cells present in
the duodenum and ileum of treated animals. Most of
these cells are secreting IgA Abs, as has been previously
reported [41, 42]. This mechanism is still unclear, as
many biologically active molecules are present in eggs
(as hormones and cytokines), which stimulate the local
immune response [2, 26, 29, 44]. This may represent
higher immune surveillance in the gut mucosa, which is
one of the main places of the entrance of infectious
Fig. 2 Group A Rotavirus (RVA) infection parameters in IgY DNT and control groups of calves. a- Kaplan-Meier survival curve of RVA infection for
both animal groups. RVA was determined in all fecal samples from diarrhea affected calves by ELISA and viral shedding onset (b) and duration (c)
were computed as average from animals on each experimental group. The AUC for the total of RVA shedding per group was also estimated (d).
The “*” indicates significant differences among the experimental groups of calves by Mann Whitney Test, with corresponding p-values expressed
on each panel
Vega et al. BMC Veterinary Research          (2020) 16:264 Page 5 of 9
agents causing illness during the first weeks of life in
calves. Another advantage of this passive treatment is
that IgY DNT is based on polyclonal IgY Abs, so it does
not induce bacterial or viral resistance. As it is a passive
treatment, IgY Abs are only present in the gut lumen
while the treatment is maintained and do not translocate
into the bloodstream. Finally, calves treated with IgY
DNT presented a healthier general condition and hair
coat compared with control ones after veterinary exam-
ination, suggesting a better nutritional and immuno-
logical status, as has been previously reported [41, 42].
Here we report a useful product for the prevention of
neonatal calf diarrhea that can be administered as an
oral passive immune strategy during the first 2 weeks of
life of dairy calves reared under artificial conditions.
Today, efforts should be made in the prevention of neo-
natal diarrhea as it is better than cure from the view-
point of not only productivity but also animal welfare.
Conclusions
The systematic immunization of pregnant cows with
good quality vaccines, the monitoring of colostrum in-
take by calves and the administration of IgY DNT during
the first 2 weeks of life could be key factors to prevent
neonatal calf diarrhea in dairy farms, reducing the un-
necessary use of antibiotics and preventing morbidity
and mortality due to this clinical condition.
Methods
Ethics statement
The protocol for animal management met the require-
ments of the Institutional Committee for Experimental
Animals Welfare and Management (CICUAE), from
INTA (protocol number 24/2010 calves and 20/2011 for
chickens). All calves were subject to veterinary assistance
following regular management protocols from the dairy
farm “El Mangrullo”.
IgY DNT production and quality control
Five hundred Lohmann Brown Classic laying hens were
immunized intramuscularly in the breasts with commer-
cially available vaccines containing bovine RVA, CoV
Mebus and E. coli J5 and Salmonella Dublin bacterin
cultures (Neonatal Block, Vetanco S.A.) under veterinary
assistance. No adverse effects on vaccination were
observed in any of the animals. Hens were immunized
following an optimized program developed especially for
IgY DNT production that has been reported elsewhere
[42]. Eggs were collected daily and processed in a spray-
dryer machine (FlexPump, Galaxie S.A.) to obtain a
powder-based product. The quality control of every
batch of this product included ELISA IgY Ab titers
against RVA, CoV, and the bacterins from E. coli J5 and
Salmonella Dublin, and microbiological control of total
aerobic microorganisms, yeasts, and fungus in compli-
ance with the United States Pharmacopeia –USP NF-
recommendations [40]. For its acceptance, each batch
should independently present an ELISA IgY Ab titer to
RVA ≥2048, and an ELISA IgY Ab titer ≥64 for CoV, E.
coli J5 and Salmonella Dublin in a solution prepared
with 40 g of IgY DNT diluted in 2 L of Ab-free milk (20
mg/mL). It also must be free of E. coli and Salmonella
sp. and show less than 10,000 colony forming units
(CFU)/g of aerobic microorganisms and less than 100
CFU/g of yeasts and fungus. This powder can be stored
at room temperature for up to 12 months [42]. All hens
remained at Bioinnovo S.A. facilities after the end of the
experiment.
Experimental design
This study was carried out in a dairy farm named “El
Mangrullo”, located in the Northeastern of Buenos Aires
Province, Argentina. The farm has 612 milking cows. A
total of 30 newborn Holstein female and male calves
were recruited for this study between September and
November 2016. Calves were born to healthy cows vac-
cinated with commercial vaccines for neonatal calf diar-
rhea and pneumonia prevention twice in the last term of
gestation. Calves were artificially fed with no less than 2
L of colostrum obtained from their dams in the first 4 h
of life and a minimum of 10% their weight (around 4–5
L) of this colostrum within the first 24 h of life. After the
first 24 h and up to the third week of life, calves were
fed with two liters of fresh bovine milk from the dairy
facilities (not pasteurized), twice a day. Only calves born
at term to healthy vaccinated cows, independently of
their sex, were included in this study. Calves born in
dystocic delivery were not recruited for this experiment.
From the third week on, the daily milk intake was of six
litters in total, divided in two intakes of three litters
each. All calves were ear-tagged during the first day of
life. The treatment assignment was performed by ran-
domly splitting all the ear tag numbers into two groups.
Animals were then assigned to the corresponding ex-
perimental group after veterinary examination: G1- IgY
DNT = calves fed with 2 L of milk supplemented with
20 g of IgY DNT powder (n = 15); and G2 - control =
calves fed with 2 L of non-supplemented milk (n = 15).
The passive treatment started after the first 24 h of life,
to assure its administration after gut closure, and was
maintained for the first 2 weeks of life (14 days in total).
The supplementation of 2 L of milk with 20 g of IgY
DNT (10mg /mL) (G1) resulted in a final ELISA IgY Ab
titer of 4096 to bovine RVA (UK G6P[5] strain); 64 to
bovine CoV (Mebus strain), 64 to enterotoxigenic E. coli
(ETEC) and 64 to Salmonella spp. (S. Dublin). Animals
were allocated in special cages with open space and a
house to protect them from weather conditions, one
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animal per cage. Calves were examined daily for the devel-
opment of diarrhea, from birth to the third week of life
(22 days-of-life). To estimate diarrhea severity, fecal
consistency was scored blindly by qualified technicians as
follows: 0 = normal; 1 = pasty; 2 = semi-liquid; 3 = liquid;
considering a score equal or greater than 2 as diarrhea
[28]. If calves developed diarrhea, fecal samples were taken
daily until the cessation of clinical symptoms. Otherwise,
fecal and serum samples were taken and rectal tempera-
tures recorded weekly, starting from the first day of life
and then at days 8, 15, and 22. The area under the curve
(AUC) of the fecal scores for each calf was determined
and then the average and median AUC for diarrhea was
calculated for each group. Animals were treated with re-
hydrating salts, antibiotics, and antipyretics if needed after
veterinarian examination. All calves remained at the dairy
farm after the end of the experiment, under regular man-
agement conditions. No long-term effect that could be
associated with this experiment was observed.
Detection of infectious agents associated with neonatal
calf diarrhea
Virus shedding (RVA and CoV) was detected in fecal
samples using antigen-capture ELISAs as previously de-
scribed [12, 33]. The AUC for daily virus shedding titers
for each calf was first determined and then the average
and median AUC for virus shedding was calculated for
the group. The presence of E. coli and Salmonella sp.
was evaluated in fecal samples by selective bacterio-
logical culture media. For E. coli detection, fecal samples
were cultured on MacConkey agar plates and Gram
staining was performed on isolated lactose-positive col-
onies. Gram-negative bacteria were biochemically char-
acterized as belonging to the Enterobacteriaceae family,
Escherichia genus, according to Bergey’s Manual. Col-
onies compatible with E. coli were transferred to tubes
containing minimal agar medium. PCR technique was
performed as described by Siqueira and colleagues [32].
The E. coli strains were classified in Shiga toxin patho-
types based on their specific virulence genes (Sta). One
calf was positive to ETEC if isolates were found to be
positive for one of the virulence genes reported else-
where [30, 31]. For Salmonella enrichment, fecal sam-
ples were 1:10 diluted in tetrathionate (TT) broth and
cultured at 37 °C for 48 h and later plated in xylose
lysine deoxycholate agar with tergitol 4 (XLDT4 agar)
for another 24 h at 37 °C. Suspicious colonies were
subject to biochemical confirmation [35].
Evaluation of bovine antibodies to viruses
Serum IgG Abs to bovine RVA (UK G6P[5] strain) and to
CoV (Mebus strain) were measured by ELISA. Virus-
specific IgG Abs were detected by indirect ELISA using the
reagents and protocols previously described [6, 7, 27, 41].
Statistical analysis
The sample size was estimated considering historical
neonatal diarrhea incidence in El Mangrullo farm and
the maximum number of calves to be born during the
experimental time proposed. For all the parameters ana-
lyzed, the statistical power was equal or above 0.8 (with
a significance level of 5%), except for diarrhea onset.
Kaplan Meier survival curves of the percentage of calves
with diarrhea and the percentage of animals infected
with RVA during the experimental time were compared
by Log-rank Mantel-Cox Test (non-parametric) using
GraphPad Prism version 5.01 for Windows (GraphPad
Software, www.graphpad.com). Fisher’s exact test was
used to compare proportions of calves with diarrhea and
virus shedding between groups. For variables like days to
onset, duration, and severity of diarrhea and virus shed-
ding, where the assumptions of normality and/or homo-
scedasticity were not met, the Mann Whitney rank sum
U-test (non-parametric) was used for comparisons be-
tween groups. IgG1 Ab titers to RVA and CoV were
log10-transformed before statistical analysis. The curves
of the kinetics of Ab response to RVA and CoV were an-
alyzed using a mixed model for repeated measures and
Bonferroni method for multiple comparisons, consider-
ing “group treatment” and “time” as fix effects and “calf”
as a random variable (varIdent) to take into account
intrinsic differences among calves and including an
auto-correlation structure of variance-covariance matrix
(corAr1). All these statistical analyses were conducted
using InfoStat [15]. In all cases, the significance level was
established at 5%.
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